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Abstract
Introduction
Fabry disease (FD) is a lysosomal storage disorder leading to decreased α-galactosidase A
enzyme activity and subsequent abnormal accumulation of glycosphingolipids in various
organs. Although histological evidence of lung involvement has been demonstrated, the
functional impact of these changes is less clear.
Materials and methods
Adult patients with FD who had yearly pulmonary function tests (PFT) at two centers from
1999 thru 2015 were eligible for this observational study. Primary outcome measures were
the change in forced expiratory volume in the first second (FEV1) and FEV1/FVC over time.
As secondary outcome we investigated sex, smoking, enzyme replacement therapy (ERT),
residual enzyme activity, and Mainz Severity Score Index as possible predictors.
Results
95 patients (41% male, 38.2 ± 14.5 years) were included. The overall prevalence of bron-
chial obstruction (BO, (FEV1/FVC < 70%)) was 46%, with male sex, age and smoking as sig-
nificant predictors. FEV1 decreased 29 ml per year (95% CI -36, -22 ml, p<0.0001). FEV1
decline was significantly higher in males (p = 0.009) and in patients on ERT (p = 0.004).
Conclusion: Pulmonary involvement seems to be a relevant manifestation of Fabry disease,
and routine PFTs should therefore be included in the multidisciplinary follow-up of these
patients.
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Introduction
Fabry disease is a rare X-linked lysosomal storage disorder due to mutations in the α-galactosi-
dase A gene (GLA) leading to deficiency or absence of α-galactosidase A (α-GAL) enzyme
activity. The enzymatic defect results in abnormal accumulation of neutral glycosphingolipids,
particularly globotriaosylceramide and galactosylceramide, in the plasma and in tissue lyso-
somes throughout the body. The lysosomal dysfunction triggers inflammation and fibrosis.
Essentially, the cells of the vascular endothelium are the main target of this disease. Thus, per-
fusion of kidneys, heart, nervous system, and skin can be impaired [1]. However, direct dam-
age from deposits in other cell types may also contribute to organ dysfunction, such as e.g.
airways and lung [2, 3].
The first patient with Fabry disease described by the German dermatologist Johannes Fabry
in 1898 was suffering from “bronchial asthma” with frequent respiratory tract infections and
died in his early forties because of respiratory impairment [4]. Subsequently, pulmonary
involvement has been considered to be a leading cause of death in Fabry disease [5]. In a recent
Fabry disease outcome survey, it was stated that pulmonary involvement was related to one of
42 deaths in Fabry patients, suggesting that it rather contributes to morbidity than to mortality
[6]. However, while histological evidence of pulmonary involvement has been demonstrated
[7–11], the functional impact of these changes is still a matter of debate [12, 13], and therefore
pulmonary involvement in Fabry disease is not uniformly acknowledged by all researchers in
this field [3]. Furthermore, the effect of enzyme replacement therapy (ERT) on pulmonary
involvement is only limited to a few reports revealing that it may stabilize the functional
decline of the lung [11, 14]. Above all, there is a paucity of data on serial pulmonary function
tests (PFTs) in Fabry patients. Therefore, the exact mechanism of a possible lung involvement
is widely unknown. The purpose of this study was to demonstrate the course of serial PFTs in
a considerably large patient cohort with Fabry disease, to characterize the pathophysiological
mechanism, and to identify patients at risk of pulmonary involvement and deterioration.
Material and methods
Patients
The University Hospitals of Zurich and Lausanne, Switzerland are conducting a shared
cohort including patients with genetically proven Fabry disease. This cohort has been estab-
lished in 1999 when ERT was in development. The patients have at least one yearly follow-
up examination at one of the two study centers. Along with PFTs, the follow-up examina-
tion contains a comprehensive workup including medical history (including cigarette
smoking history), clinical examination, complete blood and urine panel (including blood
count, blood and urine chemistry), cardiology/angiology work-up (including electrocardi-
ography, echocardiography and vessel sonography), nephrology work-up (including sonog-
raphy of the kidneys), neurology work-up (including cerebral magnetic resonance imaging)
and an ophthalmological examination. Indication for ERT is discussed at a three-monthly
interdisciplinary conference with participation of all involved disciplines. According to
local guidelines, ERT is indicated in all males. In females, ERT is indicated if they have pro-
teinuria of more than 300 mg per day, Fabry-typical kidney biopsy findings, signs of Fabry-
related cardiopathy such as left ventricular hypertrophy or arrhythmia, stroke or transient
ischemic attack, acro-paraesthesia despite conventional analgesia, and/or gastrointestinal
symptoms. ERT is prescribed at the licensed dose of either 0.2 mg/kg body weight of recom-
binant agalsidase-α (Replagal1) or 1 mg/kg body weight agalsidase-β (Fabrazyme1) and
given intravenously every 14 days.
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All adult patients of this cohort who were treated and followed-up at one of these centers
from 1999 thru 2015 were eligible for this retrospective, multi-center observational study.
Patients with less than two PFTs were excluded from the study. The study was approved by the
local Committees of Ethics of both hospitals (Ethics committee of the canton of Vaude, Lau-
sanne, Switzerland, protocol 101/01; and Ethics committee of the canton of Zurich, Switzer-
land, KEK-ZH 2012–0115), and is registered at ClinicalTrials.gov (Identifier: NCT01632111).
Pulmonary function test
Yearly PFTs included spirometry and measurement of diffusing capacity of the lung for carbon
monoxide (DLCO). Both tests were performed according to performance standards based on
the statements from the American Thoracic Society (ATS) and the European Respiratory Soci-
ety (ERS) [15, 16] at the Departments of Pulmonology of one of the centers. Bronchial obstruc-
tion was defined according to the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) [17] and ATS/ERS guidelines on chronic obstructive lung disease (COPD) [18] suggest
referring the forced expiratory volume in the first second (FEV1) to the forced (expiratory) vital
capacity (FVC) with a fixed cut-off value of below 70%. Values of DLCO were adjusted for the
patient’s current hemoglobin value, and the patients were asked to withhold cigarette smoking
at least four hours before PFT. Lung volumes and DLCO were measured with a commercial
ZAN300 CO Diffusion system (nSpire Health GmbH, Oberthulba, Germany).
Outcome measures
Primary outcome measures were the change in FEV1, FVC and DLCO over time, referring to
the age of the patients. The secondary outcome measure was to investigate on possible predic-
tors of pulmonary function changes over time. For this purpose, sex, cigarette smoking, ERT,
residual α-GAL activity, and Mainz Severity Score Index (MSSI) were assessed. The latter is a
clinical scoring system to determine the severity of Fabry disease, considering general, neuro-
logical, cardiovascular, and renal abnormalities [19].
Statistical analysis
Patient characteristics at baseline were summarized as n (%) or mean (SD), and compared
using a chi-square test or ANOVA, respectively. Changes in lung function were examined
graphically, as well as with linear mixed models. We considered a random intercept and slope
for each patient, as well as random intercept and slope for each center. However, the results
were quite similar, and therefore we report only the models with patient-specific random
effects. P-values less than 0.05 were considered statistically significant. All analyses were per-
formed in R (version 3.2.2) R Core Team (2013).
Results
From 164 eligible patients, 95 patients (59% male) with at least two PFTs were included in the
analysis (Fig 1). Baseline characteristics are displayed in Table 1. At baseline, the mean patient
age was 38.2 ± 14.5 years. Mean values of FEV1, FVC, and DLCO at baseline were above 80%
predicted, and mean FEV1/FVC was above 70%. Thirteen patients (14%) had an obstructive
lung disease. As expected, MSSI, residual α-GAL activity, and spirometric values were signifi-
cantly different between both sexes (Table 1).
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Changes of lung function over time
Of the 82 non-obstructive patients at baseline, 31 developed bronchial obstruction over time
(Fig 2). Thus, overall 44 patients (46%) had bronchial obstruction at any time point. As
expected, the proportion of pulmonary obstruction in males and smokers was higher. Interest-
ingly, the slopes of the curves were almost parallel in males compared to females (Fig 3), and
in smokers compared to non-smokers, respectively (Fig 4).
Fig 1. Patient flow chart. PFT, pulmonary function test.
https://doi.org/10.1371/journal.pone.0180437.g001
Table 1. Baseline patient characteristics, n = 95.
Variable Male Female p-value Total
(n = 56) (n = 39) (n = 95)
Age, years 39.9 (14.0) 37.0 (14.8) 0.35 38.2 (14.5)
Age at ERT * begin, years 38.0 (14.7) 39.8 (14.8) 0.61 38.9 (14.7)
Body mass index, kg/m2 23.1 (3.9) 24.3 (4.8) 0.20 23.8 (4.5)
Current or former cigarette smoking 26 (72.2) 36 (67.9) 0.84 62 (69.7)
- Pack-years 21.3 (14.4) 12.1 (8.0) 0.04 15.7 (11.7)
MSSI ll 23.1 (16.7) 11.2 (8.3) <0.0001 16.1 (13.7)
Residual α-GAL † activity, % 8.6 (10.2) 53.2 (35.6) <0.0001 41.5 (35.2)
FEV1 ‡, litres 2.9 (0.8) 2.5 (0.5) 0.0029 2.7 (0.7)
FEV1 ‡, % predicted 79.7 (18.2) 89.9 (16.1) 0.0052 85.7 (17.6)
FVC §, litres 4.1 (0.8) 3.2 (0.6) <0.0001 3.6 (0.8)
FVC §, % predicted 91.6 (13.1) 99.1 (15.3) 0.02 96.1 (14.9)
FEV1/FVC, % 71.1 (11.2) 77.9 (7.8) 0.00075 75.1 (9.9)
DLCO **, % predicted 86.4 (20.3) 85.2 (12.1) 0.74 85.7 (15.6)
Values are presented as n (%) for categorical variables or mean (SD) for continuous variables.
† α-GAL, α-galactosidase A activity
** DLCO, diffusing capacity of the lung for carbon monoxide
* ERT, enzyme replacement therapy
‡ FEV1, forced expiratory volume in the first second
§ FVC, forced (expiratory) vital capacity
ll MSSI, Mainz Severity Score Index
https://doi.org/10.1371/journal.pone.0180437.t001
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Overall, FEV1 decreased significantly over time (-29 ml per year, 95% CI -36 to -22 ml,
p<0.0001). Compared to this, FVC decreased -20 ml per year (95% CI -29 to -11 ml, p<0.0001),
and DLCO remained almost unchanged over time (-0.14% predicted per year, 95% CI -0.32,
0.03% predicted, p = 0.11). The slopes over time of FEV1, FVC and DLCO in percent predicted
values are illustrated in Fig 5, Fig 6 and Fig 7. The difference per additional year of age was -29 ml
Fig 2. Proportion of Fabry patients with bronchial obstruction over time. All values on y-axis are presented as percentage of patients with
bronchial obstruction which was defined as FEV1/FVC < 70%.
https://doi.org/10.1371/journal.pone.0180437.g002
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(95% CI -36, -22 ml, p<0.0001), and the reduced to -8 ml per year after adjusting for sex, smok-
ing, MSSI, baseline FEV1, enzyme activity and ERT, (95% CI -13, -3 ml, p = 0.007).
Risk factors for bronchial obstruction and FEV1 decline
In the univariable analysis age, male sex, cigarette smoking, MSSI, and ERT were associated
with pulmonary obstruction. However, only age, male sex, and smoking remained significant
Fig 3. Proportion of Fabry patients with bronchial obstruction over time, divided by sex. All values on y-axis are presented as percentage
of patients with bronchial obstruction which was defined as FEV1/FVC < 70%.
https://doi.org/10.1371/journal.pone.0180437.g003
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when considered together (Table 2). The unadjusted odds ratio for each additional year of age
was 1.23 (95% CI 1.09, 1.39, p = 0.0008), and almost the same even after adjusting for sex,
smoking, MSSI, and ERT with 1.22 (95% CI 1.10, 1.34, p = 0.001).
FEV1 decline was significantly higher in male compared to female patients (p = 0.009), and
in patients on ERT compared treatment-naïve patients (p = 0.004). Interestingly, FEV1 slopes
did not vary significantly by smoking and MSSI (Table 3). Even when considering males only,
Fig 4. Proportion of Fabry patients with bronchial obstruction over time, divided by cigarette smoking. All values on y-axis are presented
as percentage of patients with bronchial obstruction which was defined as FEV1/FVC < 70%.
https://doi.org/10.1371/journal.pone.0180437.g004
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there was no significant difference in FEV1 decline between smokers (-45ml (CI -65, -25ml)
and non-smokers (-41ml (CI -55, -27ml)), p = 0.67.
Discussion
To date, this is the largest study analyzing the long-term follow-up of pulmonary function in
Fabry disease patients. Previously, the largest cohort study on pulmonary involvement in
Fabry disease was published by Brown et al. describing 25 male Fabry disease patients of
Fig 5. Unadjusted FEV1 changes in Fabry patients over time. All measures on y-axis are displayed in percent of the predicted values.
https://doi.org/10.1371/journal.pone.0180437.g005
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whom 36% were found to have bronchial obstruction [20]. In a recent review article by our
group including 272 patients drawn from all reports on pulmonary involvement of Fabry dis-
ease, the prevalence of obstructive lung disease was 32% [3]. In the present study, the preva-
lence of bronchial obstruction was 46%. Notably, the prevalence of airflow obstruction in the
general random population in a comparable age group in Switzerland is estimated 0.9% in
women and 3.4% in men [21]. Yet, the prevalence of COPD in the general population ranges
between 5.1% and 16.7% in women, and 8.5% and 22.2% in men [22]. Thus, our results
Fig 6. Unadjusted FVC changes in Fabry patients over time. All measures on y-axis are displayed in percent of the predicted values.
https://doi.org/10.1371/journal.pone.0180437.g006
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underline a probably causative relationship between Fabry disease and bronchial obstruction,
although no conclusion concerning the pathological mechanism is permissible based on our
findings, since no lung biopsies had been taken. Yet, there are several reports suggesting that
the progressive airway narrowing is due to accumulated glycosphingolipids in the peribron-
chial or peribronchiolar cells [8–11, 20]. According to the mechanism of endothelial dysfunc-
tion in cardiomyocytes and arterial smooth-muscle cells in Fabry patients, Wang et al.
suggested that the pulmonary lysosomal accumulation of glycosphingolipids possibly leads to
Fig 7. Unadjusted DLCO changes in Fabry patients over time. All measures on y-axis are displayed in percent of the predicted values.
https://doi.org/10.1371/journal.pone.0180437.g007
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small and medium airway disease via hyperplasia of the bronchial/bronchiolar smooth muscle
cells and via insufficient smooth-muscle relaxation [10]. Thus, particularly early in the disease
process, glycosphingolipid accumulation in the bronchiolar smooth muscle cells in Fabry dis-
ease may cause small airway disease [23, 24]. In line with this, increased residual volumes as a
consequence of bronchiolar obstruction were observed in a cohort of Fabry patients without
evidence of emphysema [20]. Since there are no reliable indicators of small airway disease in
spirometry, and since we did not perform bodyplethysmographies in our patients, we are not
able to confirm the latter finding.
Unexpectedly, the overall FEV1 decline in our cohort of 29 ml per year is milder compared
to the findings of others who stated a nonlinear progression of obstructive lung disease in
Fabry disease with a yearly FEV1 decline of 40 ml [24]. However, according to our findings,
the decline was significantly faster in male patients compared to their female counterparts (38
vs. 20 ml). Interestingly, the FEV1 decline in our study is comparable to healthy non-smoking
individuals with a reported decline of 30–33 ml per year [25, 26]. And, compared to healthy
smokers with a FEV1 decline of 40–45 ml per year [25, 26] or COPD patients with 47–79 ml
per year [27], the FEV1 decline in Fabry disease patients is less severe than previously assumed.
However, it has to be taken into account that a subset of male patients in our study is clearly
more severely affected by Fabry disease, mirroring that it is characterized by considerably
Table 2. Results of generalized linear mixed models for pulmonary obstruction with random intercept and slope for each patient.
Univariable analysis Multivariable analysis
OR (95% CI) p-value OR (95% CI) p-value
Age 1.23 (1.09–1.39) 0.0008 1.22 (1.08–1.39) 0.001
Male sex 86.80 (6.06–1242.78) 0.001 17.92 (1.28–251.64) 0.032
Smoking 51.80 (2.10–1277.70) 0.016 30.48 (1.58–586.72) 0.024
MSSI ‡ 1.12 (1.00–1.25) 0.049 1.01 (0.92–1.10) 0.91
Residual α-GAL* activity 0.97 (0.93–1.01) 0.14
ERT † 451.18 (8.19–24956.63) 0.003 148.55 (0.80–27496.70) 0.06
* α-GAL, α-galactosidase A
†ERT, enzyme replacement therapy
‡MSSI, Mainz Severity Score Index
https://doi.org/10.1371/journal.pone.0180437.t002
Table 3. Comparative FEV1 slopes.
Slope FEV1*, ml (CI) p-value
Male -38 (-48, -27) 0.009
Female -20 (-30, -11)
Smoker -33 (-47, -19)
Non-smoker -29 (-38, -20) 0.60
ERT† -31 (-39, -24)
ERT† naive 23 (-32, -14) 0.004
MSSI‡, 0–20 points -28 (-38, -17)
MSSI‡, 20–40 points -31 (-46, -15) 0.33
MSSI‡, 40–60 points -41 (-73, -10)
†ERT, enzyme replacement therapy
* FEV1, forced expiratory volume in first second
‡MSSI, Mainz Severity Score Index
https://doi.org/10.1371/journal.pone.0180437.t003
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heterogeneous phenotypes. FEV1 decline in those patients is exceeding 40 ml per year, but
appropriate tools to prospectively identify these severely affected patients in consideration of
pulmonary involvement are lacking. Accordingly, MSSI was not associated with FEV1 decline
in this study.
Compared to others, the impact of smoking on FEV1 decline in Fabry disease seems to be
less clear [20, 28]. A possible explanation for these conflicting results could be due to heteroge-
neity of the reported cohorts. The subjects included in the cohort by Aubert et al. [28] were
younger compared to the cohort reported by Brown et al. [20].
Interestingly, FEV1 decline was not improved by ERT, though ERT seems to be an indicator
of marked disease severity. A possible reason for this observation could be that the initiation of
ERT was relatively late. Hence, a high proportion of the patients could already have had bron-
chial/bronchiolar glycosphingolipid depositions, and early initiation of ERT might have pre-
vented pulmonary disease progression. Regarding the efficacy of ERT on heart and kidney
involvement, there is a probable decelerating effect on disease progression, when started prior
to the onset of fibrosis [29–31]. However, there are still a lot of open questions in terms of initi-
ation and duration of ERT, dosage, and the clinical relevance of the various endpoints used in
the trials [32]. Furthermore, there are only limited and conflicting data on the effect of ERT on
pulmonary function. In two small retrospective studies, ERT has been reported to stabilize or
even ameliorate the burden of pulmonary involvement in Fabry disease, mainly bronchial
obstruction and/or sleep apnea [10, 14]. Opposed to this, in one small retrospective cross-sec-
tional case series of 15 Fabry disease patients no significant lung function changes were
observed in serial spirometries and DLCO measurements during a period of 15 months after
initiation of ERT [33]. Our study was not specifically designed and powered to answer this
question. Future prospective studies should include PFTs as pre-defined endpoints, and adjust
the analysis for potential confounding factors (e.g. smoking) [3]. Further investigations should
clarify whether early ERT initiation can preserve pulmonary function. Clinical trials are also
warranted in order to elucidate if inhaled bronchodilators on top of ERT are effective in
patients with Fabry disease-related pulmonary obstruction.
Several limitations of this study merit consideration. Firstly, we used the GOLD criterion
that defines bronchial obstruction as a FEV1/FVC < 70% rather than z-scores, although the
GOLD guidelines misidentify a relevant proportion of abnormal younger adults as normal
[34, 35]. Thus, it is possible that the prevalence of bronchial obstruction in our cohort is even
higher than reported. However, it was not possible ad re-calculate all data, since some of them
are several years old, and, comparison to older references is more accurate by using the GOLD
criterion. Secondly, interpretation of our findings concerning the therapy effects should take
into account that our study is not randomized and lacks a placebo-controlled group.
Conclusions
Pulmonary involvement seems to be a relevant, but underestimated manifestation of Fabry
disease, and routine PFTs should therefore be included in the multidisciplinary follow-up of
these patients. However, additional studies are needed to investigate appropriate tools to pro-
spectively identify patients at risk for pulmonary involvement, and whether early diagnosis
and treatment initiation may prevent pulmonary disease progression before the onset of
advanced bronchial/bronchiolar changes due to glycosphingolipid depositions.
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